CMS hesitates to approvePET for cancer despite data
Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage.
Despite data indicating PET can influence the management of cancer patients regardless of their cancer type, National Oncologic PET Registry scientists faced a setback when the Centers for Medicare and Medicaid Services reviewed a request for expanded coverage. A CMS advisory panel came to the conclusion that clinical data for nine conditionally approved cancer indications of FDGPET were too ambivalent to support the petition.
The NOPR team suggested that making decisions case by case would be counterproductive. They remain optimistic that CMS will look favorably at the latest findings before making a final coverage decision, which is scheduled for January.
The Reading Room Podcast: Current Perspectives on the Updated Appropriate Use Criteria for Brain PET
March 18th 2025In a new podcast, Satoshi Minoshima, M.D., Ph.D., and James Williams, Ph.D., share their insights on the recently updated appropriate use criteria for amyloid PET and tau PET in patients with mild cognitive impairment.
Meta-Analysis Shows Merits of AI with CTA Detection of Coronary Artery Stenosis and Calcified Plaque
April 16th 2025Artificial intelligence demonstrated higher AUC, sensitivity, and specificity than radiologists for detecting coronary artery stenosis > 50 percent on computed tomography angiography (CTA), according to a new 17-study meta-analysis.
